We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Norwood Imm. | LSE:NIM | London | Ordinary Share | AU000A0CANX1 | ORD SHS NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.50 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
22/5/2008 10:41 | I'm not actually a doctor I'd imagine you're the latest name from one of my 'friends' on another thread. However.... In this case, its exploiting the body's own immune system to effect therapeutic benefits. But immunology is a wider field relating to the immune system in general. | the_doctor | |
22/5/2008 10:07 | As a doctor, would you please explain to me what immunology is? tia. | gale dribble | |
22/5/2008 09:51 | bump, fell off my list | the_doctor | |
25/11/2007 09:34 | There could be some subsequent interest in use of their virosomes to deliver RNAi... : J Liposome Res. 2007;17(1):39-47. Links Cellular delivery of siRNA mediated by fusion-active virosomes.Huckriede A, De Jonge J, Holtrop M, Wilschut J. Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. RNA interference is expected to have considerable potential for the development of novel specific therapeutic strategies. However, successful application of RNA interference in vivo will depend on the availability of efficient delivery systems for the introduction of small-interfering RNA (siRNA) into the appropriate target cells. This paper focuses on the use of reconstituted viral envelopes ("virosomes"), derived from influenza virus, as a carrier system for cellular delivery of siRNA. Complexed to cationic lipid, siRNA molecules could be efficiently encapsulated in influenza virosomes. Delivery to cultured cells was assessed on the basis of flow cytometry analysis using fluorescently labeled siRNA. Virosome-encapsulate Norwood's virosome patents Patents: US 20060228376 EP1594466 Final rejection recieved in the US on 11 Nov 07 Examiner's issues to be resolved: - can the patent be limited to 1-8 carbon atoms, when the original application was 1-12 - does this matter and why have they limited in this way (presumably explained in an earlier document that I've not read yet) - substituting detergent for short-chain phospholipid could have been anticipated by Johnson et al and Hauser ######## Might be worth a punt when the patent issues are sorted out in 6 months time & if they've sorted out further finances | the_doctor | |
07/11/2007 11:22 | Ah, they raised funds earlier! A years' cash left for now. Would be interesting to see if they have any catalysts that could bring in income over the next year? Furthermore, if they have valued IP, they could be taken out? (I dont hold this stock by the way) "On 27 November 2006, the Group completed a #6.6m ($16.8m) fundraising before expenses, with the issue and placement of 55,000,000 ordinary shares" | the_doctor | |
21/8/2007 10:17 | No fundraising yet... I was thinking of calling the company to ask what their plan is? | the_doctor | |
11/7/2007 09:01 | Not sure why these guys have been out acquiring other companies when they dont have much cash. May have been bargains, but I think a fundraising may be coming shortly? | the_doctor | |
11/4/2007 16:00 | I think someone should have told them "prevention better than the cure" | hi-there | |
08/8/2006 15:20 | Over 10 million shares dumped. Anyone got any info? | justaminute.com |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |